Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 11:15:1490590.
doi: 10.3389/fimmu.2024.1490590. eCollection 2024.

Advances in biomarkers for immunotherapy in small-cell lung cancer

Hui Li  1   2 , Peiyan Zhao  1   2 , Lin Tian  1   2   3 , Yuanhua Lu  1   2   3 , Xinyue Wang  1   2   3 , Wenjun Shao  1   2   3 , Ying Cheng  1   2   4
Affiliations
Review

Advances in biomarkers for immunotherapy in small-cell lung cancer

Hui Li et al. Front Immunol. .

Abstract

Small-cell lung cancer (SCLC) is a refractory cancer with rapid growth and high aggressiveness. Extensive-stage SCLC is initially sensitive to chemotherapy; however, drug resistance and recurrence occur rapidly, resulting in a poor survival outcome due to lack of subsequently efficient therapy. The emergence of immune checkpoint inhibitors (ICIs) generated a new landscape of SCLC treatment and significantly prolonged the survival of patients. However, the unselected immunotherapy restrains both beneficiary population and responsive period in SCLC compared to the other tumors. The complex tumor origin, high heterogeneity, and immunosuppressive microenvironment may disturb the value of conventional biomarkers in SCLC including programmed cell death 1 ligand 1 and tumor mutation burden. Transcriptional regulator-based subtypes of SCLC are current research hotspot, revealing that Y (I) subtype can benefit from ICIs. Additionally, molecules related to immune microenvironment, immunogenicity, epigenetics, and SCLC itself also indicated the therapeutic benefits of ICIs, becoming potential predictive biomarkers. In this review, we discussed the advances of biomarkers for prediction and prognosis of immunotherapy, promising directions in the future, and provide reference and options for precision immunotherapy and survival improvement in patients with SCLC.

Keywords: biomarker; immunotherapy; predictive; prognosis; research advances; small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Signaling pathways and therapeutic targets relevant to SCLC.
Figure 2
Figure 2
The biomarkers associated with the efficacy of immunotherapy in SCLC.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: Cancer J For Clin. (2022) 72:7–33. doi: 10.3322/caac.21708 - DOI - PubMed
    1. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. (2017) 17:765. doi: 10.1038/nrc.2017.106 - DOI - PubMed
    1. Rhodin J, Dalhamn T. Electron microscopy of the tracheal ciliated mucosa in rat. Z Fur Zellforschung Und Mikroskopische Anatomie (Vienna Austria: 1948). (1956) 44:345–412. doi: 10.1007/BF00345847 - DOI - PubMed
    1. Huang Y-H, Klingbeil O, He X-Y, Wu XS, Arun G, Lu B, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. (2018) 32:915–28. doi: 10.1101/gad.314815.118 - DOI - PMC - PubMed
    1. George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. (2015) 524:47–53. doi: 10.1038/nature14664 - DOI - PMC - PubMed

Substances